A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis

A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis

Ursodeoxycholic acid (UDCA) is commonly used to treat several liver disorders in adults and children, including primary sclerosing cholangitis (PSC) for which it is not U.S. Food and Drug Administration approved. UDCA treatment has an uncertain impact on disease outcomes and has been reported in hig...

Full description

Bibliographic Details
Main Authors: Dennis D. Black, Cara Mack, Nanda Kerkar, Tamir Miloh, Shikha S. Sundaram, Ravinder Anand, Ashutosh Gupta, Estella Alonso, Ronen Arnon, Pinar Bulut, Saul Karpen, Chuan‐Hao Lin, Philip Rosenthal, Matthew Ryan, Robert H. Squires, Pamela Valentino, Sarah H. Elsea, Benjamin L. Shneider
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1421

Internet

https://doi.org/10.1002/hep4.1421

Similar Items